ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.